Cleveland BioLabs, Inc. (CBLI) financial statements (2021 and earlier)

Company profile

Business Address 73 HIGH STREET
BUFFALO, NY 14203
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:224915203
Cash and cash equivalents2144763
Short-term investments0015814 
Other undisclosed cash, cash equivalents, and short-term investments00(0)    
Receivables0001010
Other current assets0000000
Other undisclosed current assets(0)(0)0    
Total current assets:2241016214
Noncurrent Assets
Property, plant and equipment0000000
Long-term investments and receivables      4
Long-term investments      4
Restricted cash and investments     02
Other noncurrent assets 000000
Total noncurrent assets:0000006
TOTAL ASSETS:22510162110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0211223
Accounts payable0000001
Accrued liabilities0111222
Debt      3
Derivative instruments and hedges, liabilities 001141
Deferred revenue and credits  00
Total current liabilities:0212367
Noncurrent Liabilities
Liabilities, other than long-term debt  00   
Other liabilities  00   
Other undisclosed noncurrent liabilities      1
Total noncurrent liabilities:  00  1
Total liabilities:0212368
Stockholders' equity
Stockholders' equity attributable to parent(3)(5)(1)2810(2)
Common stock0000000
Treasury stock, value     (1) 
Additional paid in capital167163163163159159133
Accumulated other comprehensive loss(1)(1)(1)(1)(1)(0)(0)
Accumulated deficit(169)(167)(164)(160)(151)(148)(134)
Stockholders' equity attributable to noncontrolling interest5555553
Total stockholders' equity:214713152
TOTAL LIABILITIES AND EQUITY:22510162110

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net12434
Gross profit:0112434
Operating expenses(3)(3)(6)(8)(10)(13)(18)
Operating loss:(3)(3)(5)(6)(6)(11)(14)
Nonoperating income (expense)0(1)1(4)4(2)14
Investment income, nonoperating     (1)14
Foreign currency transaction gain (loss), before tax0(0)0(0)0(1)(1)
Other nonoperating income (expense)1(1)000(0)(1)
Interest and debt expense     0 
Income (loss) from continuing operations before equity method investments, income taxes:(2)(3)(4)(10)(3)(13)0
Loss from equity method investments      (0)
Loss before gain (loss) on sale of properties:(2)(3)(4)(10)(3)(13)(0)
Other undisclosed net income (loss)     (0)0
Net income (loss):(2)(3)(4)(10)(3)(13)0
Net income (loss) attributable to noncontrolling interest0000(0)02
Net income (loss) available to common stockholders, diluted:(2)(3)(4)(10)(3)(13)2

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(2)(3)(4)(10)(3)(13)0
Other undisclosed comprehensive income (loss)(0)0(0)0(0)02
Comprehensive income (loss):(3)(3)(4)(10)(3)(13)2
Comprehensive income (loss), net of tax, attributable to noncontrolling interest0000(0)02
Other undisclosed comprehensive loss, net of tax, attributable to parent      (4)
Comprehensive income (loss), net of tax, attributable to parent:(3)(3)(4)(10)(3)(13)1

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: